Published :
Tables : 55
Figures : 30
Category : Healthcare
No. of Pages : 180
Report Code : HC-1163
Immuno Oncology Assays Market to value over US $ 7.1 billion and register a CAGR of over 12.2% during the forecast period from 2020 to 2027. Increase in the incidence of cancer, advancements in technology particularly in molecular techniques, extensive research undertaken and development in cancer diagnostics, and ongoing clinical trials in cancer immunotherapy is expected to accelerate the immuno oncology assays market. According to the World Health Organization (WHO), cancer accounted for 8.8 million deaths worldwide. One out of six deaths is due to cancer. Hence, an increase in the prevalence of cancer and the rising need for personalized medicine is expected to drive the immune oncology assays market during the forecast period. With the introduction of highly sensitive molecular techniques such as next-generation sequencing (NGS) and digital PCR (dPCR), researchers and clinicians can analyze various circulating biomarkers. These innovative technologies provide an economical and minimally invasive way for diagnosis, prognosis, and therapy selection in patients throughout their treatment plan thus bolstering the market worldwide. Based on technology, the Immuno-Oncology Assays Market is segmented into PCR, immunoassay, NGS, flow cytometry, and other technologies. The NGS segment is estimated to be the segment growing with the highest CAGR during the forecast period. The integration of economical costs and advanced NGS technologies, rising government funding for sequencing projects, growing adoption of high-throughput sequencing technologies in emerging economies, and new product launches in immuno-oncology biomarker discovery are some of the key factors propelling the growth of the NGS segment. On the basis of application, the Immuno-Oncology Assays Market is segmented into research applications and clinical diagnostics. Research applications dominated the market by holding the major market share. It is also forecasted to be the fastest-growing segment during the forecast period. The rising prominence of biomarker-based drug development and clinical trials and the emergence of cancer immunotherapy are the key factors driving market growth. Based on region, North America and Europe are expected to be major markets for the immuno oncology assays market. Sound health care infrastructure and funding from public and private sectors for research and development are projected to fuel the market in these regions. According to the American Cancer Society, an estimated 1,735,350 new cancer cases will be diagnosed and 609,640 cancer deaths will occur in the U.S. Asia Pacific is expected to account for a significant share of the market during the forecast period. Federal support and innovation of novel therapeutics in the field of cancer is anticipated to drive the market in the region. Prominent Players operating in the global immuno-oncology assays industry are: Thermo Fisher Scientific, Roche Diagnostics, Agilent Technologies, Illumina, Nanostring Technologies, Inc., Sartorius AG, Foundation Medicine, HTG Molecular Diagnostics, Inc., Qiagen and Merck. Market Segmentation By Product Consumables Software By Technology PCR Immunoassay Ngs Flow Cytometry Other Technologies By Indication Lung Cancer Colorectal Cancer Melanoma Bladder Cancer Other Cancers By Application Research Applications Clinical Diagnostics By Region Europe North America APAC Latin America Rest of World Competitive Landscape: Tier 1 players- established companies in the market with a major market share Tier 2 players Emerging players which are growing rapidly New Entrants FutureWise Takeaways Growth prospects SWOT analysis Key trends Key data points affecting market growth Objectives of the Study: To provide an exhaustive analysis on the global immuno oncology assays market by product, by technology, by indication by application, and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the rest of the world To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions Profiling of companies to evaluate their market shares, strategies, financials and core competencies
Increase in the incidence of cancer, advancements in technology particularly in molecular techniques, extensive research undertaken and development in cancer diagnostics, and ongoing clinical trials in cancer immunotherapy is expected to accelerate the immuno oncology assays market. According to the World Health Organization (WHO), cancer accounted for 8.8 million deaths worldwide. One out of six deaths is due to cancer. Hence, an increase in the prevalence of cancer and the rising need for personalized medicine is expected to drive the immune oncology assays market during the forecast period. With the introduction of highly sensitive molecular techniques such as next-generation sequencing (NGS) and digital PCR (dPCR), researchers and clinicians can analyze various circulating biomarkers. These innovative technologies provide an economical and minimally invasive way for diagnosis, prognosis, and therapy selection in patients throughout their treatment plan thus bolstering the market worldwide.
Based on technology, the Immuno-Oncology Assays Market is segmented into PCR, immunoassay, NGS, flow cytometry, and other technologies. The NGS segment is estimated to be the segment growing with the highest CAGR during the forecast period. The integration of economical costs and advanced NGS technologies, rising government funding for sequencing projects, growing adoption of high-throughput sequencing technologies in emerging economies, and new product launches in immuno-oncology biomarker discovery are some of the key factors propelling the growth of the NGS segment.
On the basis of application, the Immuno-Oncology Assays Market is segmented into research applications and clinical diagnostics. Research applications dominated the market by holding the major market share. It is also forecasted to be the fastest-growing segment during the forecast period. The rising prominence of biomarker-based drug development and clinical trials and the emergence of cancer immunotherapy are the key factors driving market growth.
Based on region, North America and Europe are expected to be major markets for the immuno oncology assays market. Sound health care infrastructure and funding from public and private sectors for research and development are projected to fuel the market in these regions. According to the American Cancer Society, an estimated 1,735,350 new cancer cases will be diagnosed and 609,640 cancer deaths will occur in the U.S. Asia Pacific is expected to account for a significant share of the market during the forecast period. Federal support and innovation of novel therapeutics in the field of cancer is anticipated to drive the market in the region.
Prominent Players operating in the global immuno-oncology assays industry are:
Thermo Fisher Scientific, Roche Diagnostics, Agilent Technologies, Illumina, Nanostring Technologies, Inc., Sartorius AG, Foundation Medicine, HTG Molecular Diagnostics, Inc., Qiagen and Merck.
Market Segmentation
By Product
By Technology
By Indication
By Application
By Region
Competitive Landscape:
FutureWise Takeaways
Objectives of the Study:
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Immuno Oncology Assays Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Immuno Oncology Assays Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Immuno Oncology Assays Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Immuno Oncology Assays Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Immuno Oncology Assays Market, By Product Historical Analysis and Forecast 2020-2027 (USD Million) 7.1 Consumables 7.2 Software 8. Global Immuno Oncology Assays Market, By Technology Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. PCR 8.2. Immunoassay 8.3. Ngs 8.4. Flow Cytometry 8.5. Other Technologies 9. Global Immuno Oncology Assays Market, By Indication Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. Lung Cancer 9.2. Colorectal Cancer 9.3. Melanoma 9.4. Bladder Cancer 9.5. Other Cancers 10. Global Immuno Oncology Assays Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million) 10.1. Research Applications 10.2. Clinical Diagnostics 11. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2020-2027 12. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2020-2027 13. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2020-2027 14. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027 15. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 15.2.1. Saudi Arabia 15.2.2. UAE 15.2.3. South Africa 15.2.4. Egypt 15.3. Market Size (USD Million) Forecast for MEA 2020-2027 16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts) 16.1 Thermo Fisher Scientific, Inc. 16.1.1. Company Overview (HQ, Business Segments, Employee Strength) 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2 Roche Diagnostics 16.2.1. Company Overview (HQ, Business Segments, Employee Strength) 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3 Agilent Technologies, Inc. 16.3.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4 Illumina, Inc. 16.4.1. Company Overview (HQ, Business Segments, Employee Strength) 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5 Nanostring Technologies, Inc. 16.5.1. Company Overview (HQ, Business Segments, Employee Strength) 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6 Sartorius AG 16.6.1. Company Overview (HQ, Business Segments, Employee Strength) 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7 Foundation Medicine 16.7.1. Company Overview (HQ, Business Segments, Employee Strength) 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8 HTG Molecular Diagnostics, Inc. 16.8.1. Company Overview (HQ, Business Segments, Employee Strength) 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9 Qiagen 16.9.1. Company Overview (HQ, Business Segments, Employee Strength) 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10 Merck 16.10.1. Company Overview (HQ, Business Segments, Employee Strength) 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview 16.11 Perkinelmer 16.11.1. Company Overview (HQ, Business Segments, Employee Strength) 16.11.2. Product Portfolio 16.11.3. SWOT Analysis 16.11.4. Financial Overview 16.11.5. Strategic Overview 17. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics